Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327183 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 532
- Enrollment target
NCT01327183: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT01327183 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 532 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (300% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01327183, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 532 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in patients with non ST-elevation myocardial infarction (Non-STEMI) undergoing percutaneous coronary intervention (PCI). Patients will be randomized to receive an intravenous infusion of either 5 mg/kg RO4905417 or 20 mg/kg RO4905417 or placebo before PCI. Follow-up will be for 4 months.
Interventions
- DRUG placebo
- PROCEDURE Percutaneous Coronary Intervention (PCI)
- DRUG RO4905417
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT01327183 record still lists
NCT01327183 is an interventional study that assigns participants to a tested intervention. The registered 532 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (300% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01327183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01327183 about?
NCT01327183 is a clinical study titled "A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention". This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in patients with non ST-elevation myocardial infarction (Non-STEMI) undergoing percutaneous coronary intervention (PCI). Patients will be randomized to receive an intravenous infusion of either...
What is the current status of trial NCT01327183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 532 participants. The study started on 2011-05. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01327183?
The interventions under investigation include: placebo (DRUG), Percutaneous Coronary Intervention (PCI) (PROCEDURE), RO4905417 (DRUG).
Who is sponsoring clinical trial NCT01327183?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01327183's enrollment target sits among peer trials
532 64th of 2000 higher than 1,937 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- NCT06378866 · 532 participants · Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- NCT07219173 · 531 participants · Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia